New combo aims to tackle Hard-to-Treat breast cancer
NCT ID NCT07446452
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of two drugs—disitamab vedotin and bevacizumab—in 37 people with HER2-low metastatic breast cancer whose disease progressed after prior T-DXd therapy. The goal is to see if the combo can shrink tumors and delay progression. Researchers will also study side effects and look for biomarkers that predict who benefits most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
disitamab vedotin (a targeted drug) combined with bevacizumab (an anti-angiogenesis drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with HER2-low breast cancer whose disease has worsened after prior therapy.
What could go wrong
This is a small, early-phase trial (37 people) with no control group, so results may not be definitive. Side effects from the drug combination could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-LOW BREAST CANCER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••